Evidence map›Paper›PMID 39146495›Full record

ArticleBlood advances2024

Addressing financial hardship in malignant hematology and hematopoietic cell transplant: a team approach.

Salene M W Jones, Timothy J D Ohlsen, Kristine A Karvonen, Mohamed Sorror

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Salene M W JonesPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0003-2140-5798
Timothy J D OhlsenDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, WA.ORCID 0000-0002-1098-2330
Kristine A KarvonenDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, WA.
Mohamed SorrorClinical Research Division, Fred Hutchinson Cancer Center and Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0001-5260-1981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractFinancial hardship is a common experience for patients and their families after the diagnosis of a hematologic malignancy and is associated with worse outcomes. Health care costs, increased costs of living, income poverty, and inadequate wealth contribute to financial hardship after the diagnosis and treatment of a hematologic malignancy and/or hematopoietic cell transplant. Given the multidimensional nature of financial hardship, a multidisciplinary team-based approach is needed to address this public health hazard. Hematologists and oncologists may mitigate the impact of financial hardship by matching treatment options with patient goals of care and reducing symptom burden disruptive to employment. Social workers and financial navigators can assist with screening and resource deployment. Policymakers and researchers can identify structural and policy changes to prevent financial hardship. By alleviating this major health care burden from patients, care teams may improve survival and quality of life for patients with hematologic malignancies.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationCost of IllnessFinancial StressHumansPatient Care TeamQuality of Life

Identifiers

PMID39146495
PMCPMC11470286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.